In the discovery stage, quickly obtaining the pathogen gene sequence is usually the first critical step for developing vaccines and therapeutic drugs. The next step is to study the mechanism of the pathogen's entry into cells and its structure, function, and immunogenicity. The epitope (also known as antigenic determinant) is the part of the antigen recognized by the immune system that stimulates the immunogenic response. Therefore a deep understanding of the epitope distribution and types provides an essential foundation for vaccine development.
With the development of immunology research, scientists and physicians have discovered new uses for vaccines, such as to treat some intractable diseases. Therefore, vaccines can have both preventive and therapeutic functions. Therapeutic vaccines belong to specific active immunotherapy, especially tumor therapeutic vaccines are at an important stage of development.
Through the years, vaccine technologies have undergone many evolutions, and new vaccine types have been developed. GenScript provides comprehensive solutions for the development of new generations of vaccines, such as recombinant protein vaccines, peptide vaccines, mRNA vaccines, DNA vaccines, and viral vector vaccines.
In response to vaccination, the immune system develops innate and adaptive immune responses. The innate immune response is triggered immediately to new pathogens not present in the host. The more specific adaptive immune response is developed later and consists of antibody and cellular response. Therefore the level of the vaccine antigen is important in order to generate sufficient adaptive immune response. GenScript can support vaccine development as well as the development of vaccine-specific measuring assays such as neutralizing ELISAs and pseudovirus neutralization tests.
The focus of clinical trials is to investigate the safety and effectiveness of vaccines, including the evaluation of vaccine protection efficacy and the exploration of the correlation between immunogenicity indicators and protection. Therefore vaccine samples for clinical trials should be produced under GMP conditions. GenScript can provide RUO and GMP grades of key materials used in vaccine development in research and clinical stages to fully support you in successfully launching vaccines.
GenScript supports vaccine development helping you meet different quality requirements in all production stages, from early research to clinical trials.
|IND||Phase 1||Phase 2||Phase 3||BLA/
|GenCircle dsDNA Vector||Industrial Grade||Preclinical Grade|
|Plasmid Preparation||Research Grade||Industrial Grade||Preclinical Grade||IND CMC||GMPro Grade||GMP Grade|
|Plasmid Linearization||Research Grade||Industrial Grade||Preclinical Grade||IND CMC||GMPro Grade||GMP Grade|
|IVT mRNA Production Service||Research Grade||Preclinical Grade|
|Protein Expression Service||TurboCHO™- HT||TurboCHO™-Express||TurboCHO™- HP||IND CMC||Biologics GMP Grade|
|AAV Vector Service||Pro Grade||AAV CMC||Clinical GMP Grade|
|Lentiviral Vector Service||Research Grade||Pro Grade||LVV CMC||Clinical GMP Grade||GMP Grade|
|Peptide Synthesis||Research Grade||GMP Grade|
Explore our technologies and learn more about Vaccine Development Solutions. Find the information and resources you need by browsing through our educational material.
Josh Wang, Ph.D.
R&D Sr. Scientist Genscript USA Inc.
Dr. Howwing Leung
Field Application Scientist, GenScript